GPS is based on a combination of CRP and albumin and has been evaluated in a variety of cancers, such as renal cancer, breast cancer, non-small cell lung cancer, gastroesophageal cancer, pancreatic cancer, and colorectal cancer [19-24]. This evidence concerns the gene ALB and non-small cell lung carcinoma.